About the Authors
- Evelyn Klein
-
Affiliation Department of Gynecology and Obstetrics, Klinikum Rechts der Isar, TU München, Munich, Germany
- Dietmar Schlembach
-
Current address: Vivantes Clinics Neukölln, Clinic of Obstetrics, Berlin, Germany
Affiliation Dept. of Obstetrics, University Hospital, Jena, Germany
- Angela Ramoni
-
Affiliation Department of Obstetrics and Gynecology, University Hospital of Innsbruck, Innsbruck, Austria
- Elena Langer
-
Affiliation Department of Obstetrics, Leipzig University, Leipzig, Germany
- Franz Bahlmann
-
Affiliation Department of Obstetrics, Bürgerhospital, Frankfurt, Germany
- Sabine Grill
-
Affiliation Department of Gynecology and Obstetrics, Klinikum Rechts der Isar, TU München, Munich, Germany
- Helene Schaffenrath
-
Affiliation Department of Obstetrics and Gynecology, University Hospital of Innsbruck, Innsbruck, Austria
- Reinhard van der Does
-
Affiliation IST GmbH, Mannheim, Germany
- Diethelm Messinger
-
Affiliation IST GmbH, Mannheim, Germany
- Wilma D. J. Verhagen-Kamerbeek
-
Affiliation Medical and Scientific Affairs, Roche Diagnostics International Ltd, Rotkreuz, Switzerland
- Manfred Reim
-
Affiliation Medical and Scientific Affairs, Roche Diagnostics GmbH, Penzberg, Germany
- Martin Hund
-
Affiliation Medical and Scientific Affairs, Roche Diagnostics International Ltd, Rotkreuz, Switzerland
- Holger Stepan
-
* E-mail: Holger.Stepan@medizin.uni-leipzig.de
Affiliation Department of Obstetrics, Leipzig University, Leipzig, Germany
Competing Interests
DS and HSt are consultants for Roche Diagnostics. RvdD is an employee of IST GmbH, contracted by Roche Diagnostics. DM was an employee of IST GmbH, contracted by Roche Diagnostics, at the time of the study. WDJV-K, MR and MH are employees of Roche Diagnostics. MH also holds stock in F. Hoffmann-La Roche AG. In addition, MH reports a pending patent related to the sFlt- 1/PlGF or endoglin/PlGF ratio to rule out onset of preeclampsia in pregnant women within a certain time period (PCT/EP2013/063115), and pending patents related to the dynamic of sFlt-1 or endoglin/PlGF ratio as an indicator for imminent preeclampsia and/or HELLP syndrome (PCT/EP2012/072157) and the prediction of postpartum HELLP syndrome, postpartum eclampsia or postpartum preeclampsia (PCT/EP2015/051457). ELECSYS® and COBAS® are trademarks of Roche. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.
Author Contributions
Conceived and designed the experiments: RvdD DM MH. Performed the experiments: EK DS AR EL SG H. Stepan H. Schaffenrath. Analyzed the data: EK RvdD DM WDJV-K MR MH H. Stepan. Contributed reagents/materials/analysis tools: DS FB WDJV-K. Wrote the paper: EK DS AR EL FB SG H. Schaffenrath RvdD DM WDJV-K MR MH H. Stepan.